26 results on '"Secher AL"'
Search Results
2. Charge identification of fragments with the emulsion spectrometer of the FOOT experiment
- Author
-
Galati Giuliana, Alexandrov Andrey, Alpat Behcet, Ambrosi Giovanni, Argirò Stefano, Diaz Raul Arteche, Bartosik Nazar, Battistoni Giuseppe, Belcari Nicola, Bellinzona Elettra, Biondi Silvia, Bisogni Maria Giuseppina, Bruni Graziano, Carra Pietro, Cerello Piergiorgio, Ciarrocchi Esther, Clozza Alberto, Colombi Sofia, Guerra Alberto Del, De Simoni Micol, Di Crescenzo Antonia, Di Ruzza Benedetto, Donetti Marco, Dong Yunsheng, Durante Marco, Faccini Riccardo, Ferrero Veronica, Fiandrini Emanuele, Finck Christian, Fiorina Elisa, Fischetti Marta, Francesconi Marco, Franchini Matteo, Franciosini Gaia, Galli Luca, Gentile Valerio, Giraudo Giuseppe, Hetzel Ronja, Iarocci Enzo, Ionica Maria, Iuliano Antonio, Kanxheri Keida, Kraan Aafke Christine, Lante Valeria, La Tessa Chiara, Laurenza Martina, Lauria Adele, Torres Ernesto Lopez, Marafini Michela, Massimi Cristian, Mattei Ilaria, Mengarelli Alberto, Moggi Andrea, Montesi Maria Cristina, Morone Maria Cristina, Morrocchi Matteo, Muraro Silvia, Murtas Federica, Pastore Alessandra, Pastrone Nadia, Patera Vincenzo, Pennazio Francesco, Placidi Pisana, Pullia Marco, Raffaelli Fabrizio, Ramello Luciano, Ridolfi Riccardo, Rosso Valeria, Sanelli Claudio, Sarti Alessio, Sartorelli Gabriella, Sato Osamu, Savazzi Simone, Scavarda Lorenzo, Schiavi Angelo, Schuy Christoph, Scifoni Emanuele, Sciubba Adalberto, Sécher Alexandre, Selvi Marco, Servoli Leonello, Silvestre Gianluigi, Sitta Mario, Spighi Roberto, Spiriti Eleuterio, Sportelli Giancarlo, Stahl Achim, Tioukov Valeri, Tomassini Sandro, Tommasino Francesco, Toppi Marco, Traini Giacomo, Valle Serena Marta, Vanstalle Marie, Villa Mauro, Weber Ulrich, Zarrella Roberto, Zoccoli Antonio, and De Lellis Giovanni
- Subjects
particle therapy ,nuclear emulsion ,fragmentation ,Physics ,QC1-999 - Abstract
The FOOT (FragmentatiOn Of Target) experiment is an international project designed to carry out the fragmentation cross-sectional measurements relevant for charged particle therapy (CPT), a technique based on the use of charged particle beams for the treatment of deep-seated tumors. The FOOT detector consists of an electronic setup for the identification of Z≥3Z\ge 3 fragments and an emulsion spectrometer for Z≤3Z\le 3 fragments. The first data taking was performed in 2019 at the GSI facility (Darmstadt, Germany). In this study, the charge identification of fragments induced by exposing an emulsion detector, embedding a C2H4{{\rm{C}}}_{2}{{\rm{H}}}_{4} target, to an oxygen ion beam of 200 MeV/n is discussed. The charge identification is based on the controlled fading of nuclear emulsions in order to extend their dynamic range in the ionization response.
- Published
- 2021
- Full Text
- View/download PDF
3. Screening for type 2 diabetes and hypertension in seafarers' medical examinations.
- Author
-
Jensen OC, Flores A, Corman V, Canals ML, Lucas D, Denisenko I, Lucero-Prisno DE, Secher AL, Andersen GS, Jørgensen ME, Pujol HE, Cohen G, and Gyntelberg F
- Subjects
- Glucose, Humans, Public Health, Ships, Diabetes Mellitus, Type 2 diagnosis, Hypertension diagnosis
- Abstract
Background: The aims of the study are: 1) to replace the urine glucose test for diabetes with more than 50% false negatives, with an accurate screening for type 2 diabetes and hypertension in the mandatory biannual fit-for-duty medical examinations of seafarers; 2) to produce data driven "Green Ship" health pro-motion in the ships. A new health promotion and disease prevention public health intervention programme integrated in the fit-for-duty medical examinations for seafarers is being developed., Materials and Methods: The lack of an accurate diagnosis of type 2 diabetes is replaced by accurate HbA1c and/or fasting glucose tests and the test for hypertension in various disease stages is based on the International Associations' Guidelines. A "Green Ship" health promotion programme is proposed for all on board, not only for diseased crew members., Results: A protocol for an accurate biannual screening for diabetes and hypertension is presented. Educational programmes for medical doctors and seafarers on the management of hypertension and diabetes on board will be developed. Presuming that all crew members are potentially on their way to be pre-diseased or are diseased, the "Green Ship" health promotion programme is implemented for the whole crew., Conclusions: The International Labour Organization and the National Maritime Authorities are prompted to revise the International and the National Guidelines for Seafarers Medical Examinations, respectively. Con-certed actions are requested to implement public health promotion projects in shipping. Maritime medical doctors are prompted to use health dialogues and to report the clinical data in the Excel file. Sustainability is obtained by complying with the Sustainable Development Goals (3, 4, 8, 10, and 17).
- Published
- 2022
- Full Text
- View/download PDF
4. Correction to: Flash glucose monitoring and automated bolus calculation in type 1 diabetes treated with multiple daily insulin injections: a 26 week randomised, controlled, multicentre trial.
- Author
-
Secher AL, Pedersen-Bjergaard U, Svendsen OL, Gade-Rasmussen B, Almdal T, Raimond L, Vistisen D, and Nørgaard K
- Published
- 2022
- Full Text
- View/download PDF
5. Flash glucose monitoring and automated bolus calculation in type 1 diabetes treated with multiple daily insulin injections: a 26 week randomised, controlled, multicentre trial.
- Author
-
Secher AL, Pedersen-Bjergaard U, Svendsen OL, Gade-Rasmussen B, Almdal T, Raimond L, Vistisen D, and Nørgaard K
- Subjects
- Adult, Blood Glucose, Glycated Hemoglobin analysis, Humans, Hypoglycemic Agents therapeutic use, Insulin therapeutic use, Middle Aged, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1 drug therapy
- Abstract
Aims/hypothesis: We aimed to compare the effects of intermittently scanned continuous glucose monitoring (isCGM) and carbohydrate counting with automated bolus calculation (ABC) with usual care., Methods: In a randomised, controlled, open-label trial carried out at five diabetes clinics in the Capital Region of Denmark, 170 adults with type 1 diabetes for ≥1 year, multiple daily insulin injections and HbA
1c > 53 mmol/mol (7.0%) were randomly assigned 1:1:1:1 with centrally prepared envelopes to usual care (n = 42), ABC (n = 41), isCGM (n = 48) or ABC+isCGM (n = 39). Blinded continuous glucose monitoring data, HbA1c and patient-reported outcomes were recorded at baseline and after 26 weeks. The primary outcome was change in time in range using isCGM vs usual care., Results: Baseline characteristics were comparable across arms: mean age 47 (SD 13.7) years, median (IQR) diabetes duration 18 (10-28) years and HbA1c 65 (61-72) mmol/mol (8.1% [7.7-8.7%]). Change in time in range using isCGM was comparable to usual care (% difference of 3.9 [-12-23], p = 0.660). The same was true for the ABC and ABC+isCGM arms and for hypo- and hyperglycaemia. Also compared with usual care, using ABC+isCGM reduced HbA1c (4 [95% CI 1, 8] mmol/mol) (0.4 [0.1, 0.7] %-point) and glucose CV (11% [4%, 17%]) and improved treatment satisfaction, psychosocial self-efficacy and present life quality. Treatment satisfaction also improved by using isCGM alone vs usual care. Statistical significance was maintained after multiple testing adjustment concerning glucose CV and treatment satisfaction with ABC+isCGM, and treatment satisfaction with isCGM. Discontinuation was most common among ABC only users, and among completers the ABC was used 4 (2-5) times/day and the number of daily isCGM scans was 5 (1-7) at study end., Conclusions/interpretation: isCGM alone did not improve time in range, but treatment satisfaction increased in technology-naive people with type 1 diabetes and suboptimal HbA1c . The combination of ABC+isCGM appears advantageous regarding glycaemic variables and patient-reported outcomes, but many showed resistance towards ABC., Trial Registration: ClinicalTrials.gov NCT03682237., Funding: The study is investigator initiated and financed by the Capital Region of Denmark., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2021
- Full Text
- View/download PDF
6. Study protocol for optimising glycaemic control in type 1 diabetes treated with multiple daily insulin injections: intermittently scanned continuous glucose monitoring, carbohydrate counting with automated bolus calculation, or both? A randomised controlled trial.
- Author
-
Secher AL, Pedersen-Bjergaard U, Svendsen OL, Gade-Rasmussen B, Almdal TP, Dørflinger L, Vistisen D, and Nørgaard K
- Subjects
- Blood Glucose, Glycated Hemoglobin analysis, Glycemic Control, Humans, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1 drug therapy, Dietary Carbohydrates administration & dosage, Hypoglycemic Agents therapeutic use, Insulin therapeutic use
- Abstract
Introduction: There are beneficial effects of advanced carbohydrate counting with an automatic bolus calculator (ABC) and intermittently scanned continuous glucose monitoring (isCGM) in persons with type 1 diabetes. We aim to compare the effects of isCGM, training in carbohydrate counting with ABC and the combination of the two concepts with standard care., Methods and Analysis: A multi-centre randomised controlled trial with inclusion criteria: ≥18 years, type 1 diabetes ≥1 year, injection therapy, HbA1c >53 mmol/mol, whereas daily use of carbohydrate counting and/or CGM/isCGM wear are exclusion criteria. Inclusion was initiated in October 2018 and is ongoing. Eligible persons are randomised into four groups: standard care, ABC, isCGM or ABC+isCGM. Devices used are FreeStyle Libre Flash and smart phone diabetes application mySugr. Participants attend group courses according to treatment allocation with different educational contents. Participants are followed for 26 weeks with clinical visits and telephone consultations. At baseline and at study end, participants wear blinded CGM, have blood samples performed and fill in questionnaires on person-related outcomes, and at baseline also on personality traits and hypoglycaemia awareness. The primary outcome is the difference in time spent in normoglycaemia (4-10 mmol/L) at study end versus baseline between the isCGM group and the standard care group. Secondary outcomes will also be analysed. Results are expected in 2020., Ethics and Dissemination: Regional Scientific Ethics Committee approval (H-17040573). Results will be sought disseminated at conferences and in high impact journals.Trial registration numberClinicalTrial.gov registry (NCT03682237)., Competing Interests: Competing interests: KN is a shareholder of Novo Nordisk; has received research support from Novo Nordisk, Roche Diagnostics, Dexcom and Zealand Pharma; has received lecture fees from Medtronic, Roche Diagnostics, Rubin Medical, Sanofi, Zealand Pharma, Novo Nordisk and Dexcom and has served on advisory panels for Medtronic, Abbott and Novo Nordisk. UP-B has served on advisory boards for AstraZeneca, Bristol-Myers Squibb, Sanofi-Aventis, Novo Nordisk and Zealand Pharma and has received lecture fees from AstraZeneca, Bristol-Myers Squibb, Sanofi-Aventis and Novo Nordisk. TPA holds stocks in Novo Nordisk. ALS, OLS, BG-R, LD and DV do not have any competing interests., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
7. Breastfeeding at night is rarely followed by hypoglycaemia in women with type 1 diabetes using carbohydrate counting and flexible insulin therapy.
- Author
-
Ringholm L, Roskjær AB, Engberg S, Andersen HU, Secher AL, Damm P, and Mathiesen ER
- Subjects
- Adult, Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1 drug therapy, Female, Humans, Infant, Mothers, Postpartum Period, Pregnancy, Breast Feeding, Diabetes Mellitus, Type 1 blood, Hypoglycemia blood, Hypoglycemic Agents therapeutic use, Insulin therapeutic use, Lactation blood
- Abstract
Aims/hypothesis: Hypoglycaemia in association with breastfeeding is a feared condition in mothers with type 1 diabetes. Thus, routine carbohydrate intake at each breastfeed, particularly at night, is often recommended despite lack of evidence. We aimed to evaluate glucose levels during breastfeeding, focusing on whether night-time breastfeeding induced hypoglycaemia in mothers with type 1 diabetes., Methods: Of 43 consecutive mothers with type 1 diabetes, 33 (77%) were included prospectively 1 month after a singleton delivery. Twenty-six mothers (mean [SD] age 30.7 [5.8] years, mean [SD] duration of diabetes 18.6 [10.3] years) were breastfeeding and seven mothers (mean [SD] age 31.7 [5.6] years, mean [SD] duration of diabetes 20.4 [6.2] years) were bottle-feeding their infants with formula. All were experienced in carbohydrate counting using individually tailored insulin therapy with insulin analogues (45% on insulin pump, 55% on multiple daily injections). Thirty-two women with type 1 diabetes, matched for age ±1 year and BMI ±1 kg/m
2 , who had not given birth or breastfed in the previous year, served as a control group. Blinded continuous glucose monitoring (CGM) for 6 days was applied at 1, 2 and 6 months postpartum in the breastfeeding mothers who recorded breastfeeds and carbohydrate intake at each CGM period. CGM was applied at 1 month postpartum in the formula-feeding mothers and once in the control women. The insulin dose was individually tailored after each CGM period., Results: The percentage of night-time spent with CGM <4.0 mmol/l was low (4.6%, 3.1% and 2.7% at each CGM period in the breastfeeding mothers vs 1.6% in the control women, p = 0.77), and the breastfeeding mothers spent a greater proportion of the night-time in the target range of 4.0-10.0 mmol/l (p = 0.01). Symptomatic hypoglycaemia occurred two or three times per week at 1, 2 and 6 months postpartum in both breastfeeding mothers and the control women. Severe hypoglycaemia was reported by one mother (3%) during the 6 month postpartum period and by one control woman (3%) in the previous year (p = 0.74). In breastfeeding mothers at 1 month, the insulin dose was 18% (-67% to +48%) lower than before pregnancy (p = 0.04). In total, carbohydrate was not consumed in relation to 438 recorded night-time breastfeeds, and CGM <4.0 mmol/l within 3 h occurred after 20 (4.6%) of these breastfeeds., Conclusions/interpretation: The percentage of night-time spent in hypoglycaemia was low in the breastfeeding mothers with type 1 diabetes and was similar in the control women. Breastfeeding at night-time rarely induced hypoglycaemia. The historical recommendation of routine carbohydrate intake at night-time breastfeeding may be obsolete in mothers with type 1 diabetes who have properly reduced insulin dose with sufficient carbohydrate intake., Trial Registration: ClinicalTrials.gov NCT02898428.- Published
- 2019
- Full Text
- View/download PDF
8. The impact of restricted gestational weight gain by dietary intervention on fetal growth in women with gestational diabetes mellitus.
- Author
-
Kurtzhals LL, Nørgaard SK, Secher AL, Nichum VL, Ronneby H, Tabor A, McIntyre HD, Damm P, and Mathiesen ER
- Subjects
- Adult, Birth Weight physiology, Blood Glucose physiology, Female, Glycated Hemoglobin metabolism, Humans, Infant, Newborn, Infant, Small for Gestational Age, Pregnancy, Retrospective Studies, Caloric Restriction, Diabetes, Gestational diet therapy, Fetal Development physiology, Gestational Weight Gain physiology, Weight Gain physiology
- Abstract
Aims/hypothesis: We aimed to investigate the impact of maternal gestational weight gain (GWG) during dietary treatment on fetal growth in pregnancies complicated by gestational diabetes (GDM)., Methods: This was a retrospective cohort study of 382 women consecutively diagnosed with GDM before 34 weeks' gestation with live singleton births in our centre (Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen, Denmark) between 2011 and 2017. The women were stratified into three groups according to restricted (53%), appropriate (16%) and excessive (31%) weekly GWG during dietary treatment (using the Institute of Medicine guidelines) to estimate compliance with an energy-restricted 'diabetes diet' (6000 kJ/day [1434 kcal/day], with approximately 50% of energy intake coming from carbohydrates with a low glycaemic index, and a carbohydrate intake of 175 g/day). Insulin therapy was initiated if necessary, according to local clinical guidelines., Results: Glucose tolerance, HbA
1c , weekly GWG before dietary treatment (difference between weight at GDM diagnosis and pre-pregnancy weight, divided by the number of weeks) and SD score for fetal abdominal circumference were comparable across the three groups at diagnosis of GDM at 276 ± 51 weeks (gestation time is given as weeksdays ). The women were followed for 100 ± 51 weeks, during which 54% received supplementary insulin therapy and the average (mean) GWG during dietary treatment was 0 kg, 3 kg and 5 kg in the three groups, respectively. Excessive weekly GWG during dietary treatment, reflecting poor dietary adherence was associated with increasing HbA1c (p = 0.014) from diagnosis of GDM to late pregnancy and infants with a birthweight-SD score of 0.59 ± 1.6. In contrast, restricted weekly GWG during dietary treatment, reflecting strict dietary adherence, was associated with decreasing HbA1c (p = 0.001) from diagnosis of GDM to late pregnancy and infants with a birthweight-SD score of 0.15 ± 1.1, without increased prevalence of infants born small for gestational age. Excessive GWG during dietary treatment and late-pregnancy HbA1c were identified as potentially modifiable clinical predictors of infant birthweight-SD score (p = 0.02 for both variables) after correction for confounders., Conclusions/interpretation: Restricted GWG during dietary treatment was associated with healthier fetal growth in women with GDM. GWG during dietary treatment and late-pregnancy HbA1c were identified as potentially modifiable clinical predictors of infant birthweight-SD score.- Published
- 2018
- Full Text
- View/download PDF
9. Use of the smartphone application "Pregnant with Diabetes".
- Author
-
Nørgaard SK, Nichum VL, Barfred C, Juul HM, Secher AL, Ringholm L, Damm P, and Mathiesen ER
- Subjects
- Blood Glucose, Denmark, Diabetes Mellitus, Type 1 therapy, Diabetes Mellitus, Type 2 therapy, Diet methods, Female, Humans, Pregnancy, Mobile Applications, Pregnancy Complications therapy, Pregnancy in Diabetics therapy, Prenatal Care methods, Smartphone statistics & numerical data
- Abstract
Introduction: The aim of this article was to evaluate the awareness and use of the smartphone application (app) "Pregnant with Diabetes" locally, nationally and internationally., Methods: In 2013, a patient initiated collaboration with the staff at Centre for Pregnant Women with Diabetes, Rigs-hospitalet, to develop the app "Pregnant with Diabetes". The app communicates clinically important antenatal health information to women with diabetes, based on recommendations from our centre. Women with pre-existing diabetes (Type 1 and Type 2 diabetes) completed an anonymous, structured questionnaire at their first antenatal visit in early pregnancy at our centre. National and international data on numbers of downloads were obtained from Google Play, from the App Store and from Google Analytics., Results: Among 139 pregnant women with diabetes (96 with Type 1 diabetes and 43 with Type 2 diabetes), 99% had a smartphone and 75% had downloaded the app, whereof 48% had obtained information from the app before their pregnancy. In July 2017, the app had been downloaded 4,465 times in Denmark and 27,361 times in a total of 183 countries. The topics most frequently visited were "diet and carbohydrates", "blood glucose" and "possible complications"., Conclusions: Easily accessible patient information made available via app technology reaches the patients and may contribute to improved pregnancy planning and outcome in women with pre-existing diabetes - locally, nationally and internationally., Funding: The app was sponsored by Novo Nordisk, Bayer A/S, Diabetes Care, Abbott, MSD Denmark, A.D.I.P.S and Rigshospitalet., Trial Registration: not relevant., (Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.)
- Published
- 2017
10. Vitamin D insufficiency, preterm delivery and preeclampsia in women with type 1 diabetes - an observational study.
- Author
-
Vestgaard M, Secher AL, Ringholm L, Jensen JB, Damm P, and Mathiesen ER
- Subjects
- Female, Humans, Pregnancy, Premature Birth prevention & control, Vitamin D blood, Vitamin D Deficiency prevention & control, Diabetes Mellitus, Type 1 blood, Pre-Eclampsia blood, Premature Birth blood, Vitamin D analogs & derivatives, Vitamin D Deficiency blood
- Abstract
Introduction: The aim of this study was to evaluate whether vitamin D insufficiency is associated with preterm delivery and preeclampsia in women with type 1 diabetes., Material and Methods: An observational study of 198 pregnant women with type 1 diabetes. 25-Hydroxy-Vitamin D and HbA1c were measured in blood samples in early (median 8 weeks, range 5-14) and late (34 weeks, range 32-36) pregnancy. Kidney involvement (microalbuminuria or nephropathy) at inclusion, smoking status at inclusion, preterm delivery (<37 weeks) and preeclampsia (blood pressure ≥140/90 mmHg and proteinuria) were registered. Vitamin D supplementation of 10 μg daily was routinely recommended., Results: Thirty-nine (20%) of the 198 women delivered preterm and 16 (8%) developed preeclampsia. Vitamin D insufficiency (<50 nmol/L) was present in 68 women (34%) in early pregnancy and in 73 women (37%) in late pregnancy. Preterm delivery occurred more frequently in women with vitamin D insufficiency in late pregnancy (27% vs. 15%, crude odds ratio 2.1; 95% confidence interval 1.0-4.3, p = 0.04). After adjustment for preexisting kidney involvement, HbA1c in late pregnancy and smoking the association became nonsignificant (adjusted odds ratio 1.8; 95% confidence interval 0.8-3.7). Preeclampsia developed in 11% of women with vitamin D insufficiency vs. 6% of the remaining women (crude odds ratio 1.8; 95% confidence interval 0.9-4.1, p = 0.25)., Conclusion: In women with type 1 diabetes, preterm delivery was twice as frequent in women with vitamin D insufficiency in late pregnancy in crude analysis, but in this small study, low vitamin D was not independently associated with preterm birth or preeclampsia., (© 2017 Nordic Federation of Societies of Obstetrics and Gynecology.)
- Published
- 2017
- Full Text
- View/download PDF
11. Translating HbA 1c measurements into estimated average glucose values in pregnant women with diabetes.
- Author
-
Law GR, Gilthorpe MS, Secher AL, Temple R, Bilous R, Mathiesen ER, Murphy HR, and Scott EM
- Subjects
- Adolescent, Adult, Blood Glucose Self-Monitoring, Female, Humans, Middle Aged, Perinatal Care, Pregnancy, Young Adult, Blood Glucose metabolism, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 1 metabolism, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 metabolism, Glycated Hemoglobin metabolism
- Abstract
Aims/hypothesis: This study aimed to examine the relationship between average glucose levels, assessed by continuous glucose monitoring (CGM), and HbA
1c levels in pregnant women with diabetes to determine whether calculations of standard estimated average glucose (eAG) levels from HbA1c measurements are applicable to pregnant women with diabetes., Methods: CGM data from 117 pregnant women (89 women with type 1 diabetes; 28 women with type 2 diabetes) were analysed. Average glucose levels were calculated from 5-7 day CGM profiles (mean 1275 glucose values per profile) and paired with a corresponding (±1 week) HbA1c measure. In total, 688 average glucose-HbA1c pairs were obtained across pregnancy (mean six pairs per participant). Average glucose level was used as the dependent variable in a regression model. Covariates were gestational week, study centre and HbA1c ., Results: There was a strong association between HbA1c and average glucose values in pregnancy (coefficient 0.67 [95% CI 0.57, 0.78]), i.e. a 1% (11 mmol/mol) difference in HbA1c corresponded to a 0.67 mmol/l difference in average glucose. The random effects model that included gestational week as a curvilinear (quadratic) covariate fitted best, allowing calculation of a pregnancy-specific eAG (PeAG). This showed that an HbA1c of 8.0% (64 mmol/mol) gave a PeAG of 7.4-7.7 mmol/l (depending on gestational week), compared with a standard eAG of 10.2 mmol/l. The PeAG associated with maintaining an HbA1c level of 6.0% (42 mmol/mol) during pregnancy was between 6.4 and 6.7 mmol/l, depending on gestational week., Conclusions/interpretation: The HbA1c -average glucose relationship is altered by pregnancy. Routinely generated standard eAG values do not account for this difference between pregnant and non-pregnant individuals and, thus, should not be used during pregnancy. Instead, the PeAG values deduced in the current study are recommended for antenatal clinical care.- Published
- 2017
- Full Text
- View/download PDF
12. Quality of life, anxiety and depression symptoms in early and late pregnancy in women with pregestational diabetes.
- Author
-
Do NC, Secher AL, Cramon P, Ringholm L, Watt T, Damm P, and Mathiesen ER
- Subjects
- Adult, Body Mass Index, Cohort Studies, Female, Humans, Linear Models, Nausea complications, Pregnancy, Surveys and Questionnaires, Vomiting complications, Weight Gain, Young Adult, Anxiety psychology, Depression psychology, Pregnancy in Diabetics psychology, Quality of Life
- Abstract
Introduction: The aim of this study was to explore changes in health-related quality of life, anxiety and depression symptoms during pregnancy in women with pregestational diabetes., Material and Methods: An observational cohort study including 137 pregnant women with pregestational diabetes (110 with type 1 and 27 with type 2). To evaluate changes from early to late pregnancy, the internationally validated questionnaires 36-Item Short-Form Health Survey (SF-36) and Hospital Anxiety and Depression Scale (HADS) were completed at 8 and 33 gestational weeks., Results: From early to late pregnancy, the SF-36 scales Physical Function, Role Physical, Bodily Pain and Physical Component Summary worsened (p < 0.0001 for all scales). Physical Component Summary score deteriorated from mean 52.3 (SD 6.5) to 40.0 (9.7) (p < 0.0001) and the deterioration was negatively associated with gestational weight gain in multiple linear regression (β = -0.34/kg, p = 0.03). The SF-36 scale Mental Health improved (p = 0.0009) and the Mental Component Summary score increased moderately from 47.6 (10.6) to 53.5 (8.6) (p < 0.0001). Greater improvement in Mental Component Summary score was seen with lower HbA1c in late pregnancy. The HADS anxiety score improved slightly from 5.0 (3.3) to 4.5 (3.4) (p = 0.04) whereas the HADS depression score remained unchanged. The prevalence of women with HADS anxiety or depression score ≥8 did not change., Conclusions: Physical quality of life deteriorated whereas mental quality of life improved slightly during pregnancy in women with pregestational diabetes. A minor reduction in anxiety and stable depression symptoms was observed. The results on mental health are reassuring, considering the great demands that pregnancy places on women with pregestational diabetes., (© 2016 Nordic Federation of Societies of Obstetrics and Gynecology.)
- Published
- 2017
- Full Text
- View/download PDF
13. Mental health in early pregnancy is associated with pregnancy outcome in women with pregestational diabetes.
- Author
-
Callesen NF, Secher AL, Cramon P, Ringholm L, Watt T, Damm P, and Mathiesen ER
- Subjects
- Adult, Cohort Studies, Denmark epidemiology, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 complications, Female, Fetal Macrosomia complications, Fetal Macrosomia epidemiology, Fetal Macrosomia psychology, Glycated Hemoglobin analysis, Humans, Pregnancy, Pregnancy in Diabetics blood, Premature Birth epidemiology, Prevalence, Psychiatric Status Rating Scales, Quality of Life, Risk, Young Adult, Anxiety complications, Depression complications, Diabetes Mellitus, Type 1 psychology, Diabetes Mellitus, Type 2 psychology, Internal-External Control, Pregnancy in Diabetics psychology, Premature Birth psychology
- Abstract
Aim: To explore the role of early pregnancy health-related quality of life, anxiety, depression and locus of control for pregnancy outcome in women with pregestational diabetes., Methods: This was a cohort study of 148 pregnant women with pregestational diabetes (118 with Type 1 diabetes and 30 with Type 2 diabetes), who completed three internationally validated questionnaires: the 36-item Short-Form Health Survey, the Hospital Anxiety and Depression Scale and the Multidimensional Health Locus of Control survey at 8 weeks. Selected pregnancy outcomes were preterm delivery (< 37 weeks) and large for gestational age infants (birth weight > 90(th) percentile). Differences between groups in the questionnaires were analysed using an unpaired t-test., Results: Women with preterm deliveries (n = 28) had lower (i.e. worse) mean (sd) quality-of-life scores for the two 36-item Short-Form Health Survey scales, Role-Emotional [58.3 (38.1) vs. 82.9 (31.3); P = 0.0005] and Mental Health [67.7 (20.4) vs. 75.2 (15.8), P = 0.04], and a lower score for the 36-item Short-Form Health Survey scale Mental Component Summary (42.8 (13.1) vs. 48.8 (9.7), P = 0.03) in early pregnancy, compared with women with term deliveries. Depression symptoms (Hospital Anxiety and Depression Scale depression score ≥ 8) were more frequent in women with preterm vs. term deliveries (seven (25%) vs. six women (5%); P = 0.003), while levels of anxiety and locus of control were similar in these two groups. No difference in early pregnancy scores for health-related quality of life, anxiety, depression and locus of control were seen in women delivering large or appropriate for gestational age infants., Conclusions: Poor mental quality of life and the presence of depressive symptoms in early pregnancy were associated with preterm delivery in women with pregestational diabetes., (© 2015 The Authors. Diabetic Medicine © 2015 Diabetes UK.)
- Published
- 2015
- Full Text
- View/download PDF
14. Fetal sonographic characteristics associated with shoulder dystocia in pregnancies of women with type 1 diabetes.
- Author
-
Secher AL, Bytoft B, Tabor A, Damm P, and Mathiesen ER
- Subjects
- Adult, Body Mass Index, Brachial Plexus injuries, Female, Fetal Weight, Glycated Hemoglobin, Humans, Pregnancy, Pregnancy Trimester, Third, Risk Factors, Ultrasonography, Prenatal, Vacuum Extraction, Obstetrical adverse effects, Young Adult, Birth Injuries diagnostic imaging, Birth Injuries epidemiology, Diabetes Mellitus, Type 1, Pregnancy in Diabetics diagnostic imaging
- Abstract
Introduction: Shoulder dystocia is a rare but severe complication of vaginal delivery and diabetic women are at high risk. The aim of this study was to identify fetal sonographic and maternal glycemic characteristics associated with shoulder dystocia in pregnant women with type 1 diabetes., Material and Methods: Twelve cases (5%) of shoulder dystocia among 241 consecutive vaginal deliveries in women with type 1 diabetes followed at Rigshospitalet University Hospital in 2009-2013 were retrospectively identified in a local database. Fetal sonographic and clinical data were compared with 69 women with type 1 diabetes and uncomplicated vaginal deliveries., Results: Women experiencing shoulder dystocia compared with women with uncomplicated deliveries had a higher glycated hemoglobin (HbA1c) in early pregnancy [median 7.0% (range 5.9-8.1) vs. 6.6% (range 5.4-10.0, P = 0.04)], whereas in late pregnancy, HbA1c in the two groups of women was comparable [6.1% (range 5.5-6.9) vs. 6.0% (range 4.7-8.4, P = 0.30)]. Fetal biometry at 36 weeks showed a higher estimated fetal weight of 3597 g (range 3051-4069) vs. 2989 g (range 2165-4025), P < 0.001, corresponding to 20% (4-41%) vs. 5% (-20 to 44%) above the mean estimated fetal weight for gestational age (P = 0.002) and a greater abdominal circumference SD score of 2.51 (range 1.56-4.20) vs. 1.33 (range -1.08 to 4.25), P = 0.001). Head circumference was comparable. Vacuum extraction was more frequent during deliveries with shoulder dystocia (58 vs. 17%, P = 0.005). Seven (58%) newborns with shoulder dystocia had brachial plexus injuries, fractures, intra-abdominal bleeding or needed resuscitation., Conclusions: Excessive estimated fetal weight and abdominal circumference at 36 weeks' sonographic examination may help in identifying diabetic women at high risk of later shoulder dystocia., (© 2015 Nordic Federation of Societies of Obstetrics and Gynecology.)
- Published
- 2015
- Full Text
- View/download PDF
15. Erratum to "Severe hypoglycemia in pregnant women with type 2 diabetes-A relevant clinical problem" [Diabetes Res. Clin. Pract. 102 (2013) e17-e18].
- Author
-
Secher AL, Mathiesen ER, Andersen HU, Damm P, and Ringholm L
- Published
- 2015
- Full Text
- View/download PDF
16. Analysis of Continuous Glucose Monitoring in Pregnant Women With Diabetes: Distinct Temporal Patterns of Glucose Associated With Large-for-Gestational-Age Infants.
- Author
-
Law GR, Ellison GT, Secher AL, Damm P, Mathiesen ER, Temple R, Murphy HR, and Scott EM
- Subjects
- Adult, Birth Weight, Blood Glucose Self-Monitoring methods, Denmark epidemiology, Diabetes Mellitus, Type 1 epidemiology, Diabetes Mellitus, Type 2 epidemiology, Female, Fetal Macrosomia epidemiology, Gestational Age, Glucose, Humans, Infant, Newborn, Pregnancy, Pregnancy in Diabetics epidemiology, United Kingdom epidemiology, Blood Glucose analysis, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 2 blood, Fetal Macrosomia blood, Pregnancy in Diabetics blood
- Abstract
Objective: Continuous glucose monitoring (CGM) is increasingly used to assess glucose control in diabetes. The objective was to examine how analysis of glucose data might improve our understanding of the role temporal glucose variation has on large-for-gestational-age (LGA) infants born to women with diabetes., Research Design and Methods: Functional data analysis (FDA) was applied to 1.68 million glucose measurements from 759 measurement episodes, obtained from two previously published randomized controlled trials of CGM in pregnant women with diabetes. A total of 117 women with type 1 diabetes (n = 89) and type 2 diabetes (n = 28) who used repeated CGM during pregnancy were recruited from secondary care multidisciplinary obstetric clinics for diabetes in the U.K. and Denmark. LGA was defined as birth weight ≥90th percentile adjusted for sex and gestational age., Results: A total of 54 of 117 (46%) women developed LGA. LGA was associated with lower mean glucose (7.0 vs. 7.1 mmol/L; P < 0.01) in trimester 1, with higher mean glucose in trimester 2 (7.0 vs. 6.7 mmol/L; P < 0.001) and trimester 3 (6.5 vs. 6.4 mmol/L; P < 0.01). FDA showed that glucose was significantly lower midmorning (0900-1100 h) and early evening (1900-2130 h) in trimester 1, significantly higher early morning (0330-0630 h) and throughout the afternoon (1130-1700 h) in trimester 2, and significantly higher during the evening (2030-2330 h) in trimester 3 in women whose infants were LGA., Conclusions: FDA of CGM data identified specific times of day that maternal glucose excursions were associated with LGA. It highlights trimester-specific differences, allowing treatment to be targeted to gestational glucose patterns., (© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.)
- Published
- 2015
- Full Text
- View/download PDF
17. Higher gestational weight gain is associated with increasing offspring birth weight independent of maternal glycemic control in women with type 1 diabetes.
- Author
-
Secher AL, Parellada CB, Ringholm L, Asbjörnsdóttir B, Damm P, and Mathiesen ER
- Subjects
- Adult, Body Mass Index, Body Weight physiology, Cohort Studies, Female, Humans, Infant, Newborn, Linear Models, Maternal Welfare, Obesity blood, Obesity physiopathology, Overweight blood, Overweight physiopathology, Pregnancy, Pregnancy Outcome, Retrospective Studies, Thinness blood, Thinness physiopathology, Birth Weight physiology, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 1 physiopathology, Glycated Hemoglobin metabolism, Hypoglycemic Agents therapeutic use, Pregnancy Complications physiopathology, Weight Gain physiology
- Abstract
Objective: We evaluate the association between gestational weight gain and offspring birth weight in singleton term pregnancies of women with type 1 diabetes., Research Design and Methods: One hundred fifteen consecutive women referred at <14 weeks were retrospectively classified as underweight (prepregnancy BMI <18.5 kg/m(2); n = 1), normal weight (18.5-24.9; n = 65), overweight (25.0-29.9; n = 39), or obese (≥30.0; n = 10). Gestational weight gain was categorized as excessive, appropriate, or insufficient according to the Institute of Medicine recommendations for each BMI class. Women with nephropathy, preeclampsia, and/or preterm delivery were excluded because of restrictive impact on fetal growth and limited time for total weight gain., Results: HbA1c was comparable at ∼6.6% (49 mmol/mol) at 8 weeks and ∼6.0% (42 mmol/mol) at 36 weeks between women with excessive (n = 62), appropriate (n = 37), and insufficient (n = 16) gestational weight gain. Diabetes duration was comparable, and median prepregnancy BMI was 25.3 (range 18-41) vs. 23.5 (18-31) vs. 22.7 (20-30) kg/m(2) (P = 0.05) in the three weight gain groups. Offspring birth weight and birth weight SD score decreased across the groups (3,681 [2,374-4,500] vs. 3,395 [2,910-4,322] vs. 3,295 [2,766-4,340] g [P = 0.02] and 1.08 [-1.90 to 3.25] vs. 0.45 [-0.83 to 3.18] vs. -0.02 [-1.51 to 2.96] [P = 0.009], respectively). In a multiple linear regression analysis, gestational weight gain (kg) was positively associated with offspring birth weight (g) (β = 19; P = 0.02) and birth weight SD score (β = 0.06; P = 0.008) when adjusted for prepregnancy BMI, HbA1c at 36 weeks, smoking, parity, and ethnicity., Conclusions: Higher gestational weight gain in women with type 1 diabetes was associated with increasing offspring birth weight independent of glycemic control and prepregnancy BMI., (© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.)
- Published
- 2014
- Full Text
- View/download PDF
18. Changes in basal rates and bolus calculator settings in insulin pumps during pregnancy in women with type 1 diabetes.
- Author
-
Mathiesen JM, Secher AL, Ringholm L, Nørgaard K, Hommel E, Andersen HU, Damm P, and Mathiesen ER
- Subjects
- Algorithms, Cohort Studies, Female, Humans, Pregnancy, Diabetes Mellitus, Type 1 drug therapy, Hypoglycemic Agents administration & dosage, Insulin administration & dosage, Insulin Infusion Systems, Pregnancy in Diabetics
- Abstract
Objective: To explore insulin pump settings in a cohort of pregnant women with type 1 diabetes on insulin pump therapy with a bolus calculator., Methods: Twenty-seven women with type 1 diabetes on insulin pump therapy were included in this study. At 8, 12, 21, 27 and 33 weeks, insulin pump settings and HbA1c were recorded. Results were compared with 96 women with type 1 diabetes on multiple daily injection therapy., Results: Throughout pregnancy, the carbohydrate-to-insulin ratio decreased at all three main meals. The most pronounced decrease was observed at breakfast, where the carbohydrate-to-insulin ratio was reduced, from median 12 (range 4-20) in early pregnancy to 3 (2-10) g carbohydrate per unit insulin in late pregnancy. Basal insulin delivery increased by ∼50%, i.e. from 0.8 (0.5-2.2) to 1.2 (0.6-2.5) IU/h at 5 a.m. and from 1.0 (0.6-1.5) to 1.3 (0.2-2.3) IU/h at 5 p.m. during pregnancy. HbA1c levels during pregnancy, the occurrence of severe hypoglycemia and pregnancy outcomes were similar in the two groups., Conclusions: In women with type 1 diabetes on insulin pump therapy with a bolus calculator, the carbohydrate-to-insulin ratio declined 4-fold from early to late pregnancy, whereas changes in basal insulin delivery were smaller.
- Published
- 2014
- Full Text
- View/download PDF
19. Real-time continuous glucose monitoring as a tool to prevent severe hypoglycaemia in selected pregnant women with Type 1 diabetes - an observational study.
- Author
-
Secher AL, Stage E, Ringholm L, Barfred C, Damm P, and Mathiesen ER
- Subjects
- Adult, Female, Humans, Hypoglycemic Agents administration & dosage, Incidence, Insulin administration & dosage, Insulin Infusion Systems, Pregnancy, Pregnancy Outcome, Risk Factors, Surveys and Questionnaires, Time Factors, Blood Glucose metabolism, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1 drug therapy, Glycated Hemoglobin metabolism, Hypoglycemia prevention & control, Hypoglycemic Agents adverse effects, Insulin adverse effects, Pregnancy in Diabetics metabolism
- Abstract
Aims: Among women with Type 1 diabetes who have had severe hypoglycaemia the year before pregnancy, 70% also experience this complication in pregnancy, and particularly in the first half of pregnancy. We evaluated whether routine use of real-time continuous glucose monitoring from early pregnancy onwards could prevent severe hypoglycaemia in these women., Methods: All 136 consecutive pregnant women with Type 1 diabetes referred to our centre were asked about severe hypoglycaemic events in the year before pregnancy and early in pregnancy at their first antenatal visit. Women with a relevant recent history were informed about their additional high risk of severe hypoglycaemia, their treatment was focused on restricted insulin doses during the first 16 gestational weeks, and they were offered real-time continuous glucose monitoring on top of self-monitored plasma glucose measurements., Results: Among 28 women with a recent history of severe hypoglycaemia, 12 (43%) used real-time continuous glucose monitoring from a median (range) of 10 (7-13) gestational weeks for 10 (1-32) weeks. Among these 12 women, eight had experienced a total of 34 (range 1-11) severe hypoglycaemic events in the year before pregnancy and nine had experienced 23 (range 1-10) events early in pregnancy. After initiation of real-time continuous glucose monitoring, two (17%) women experienced one event each. The incidence rates of severe hypoglycaemia were 2.8,17.5 and 0.3 events/patient-year. Among the 16 women in the high risk group not using real-time continuous glucose monitoring, the corresponding figures were 1.6, 5.0 and 0.1 events/patient-year., Conclusions: Further evaluation is required to determine whether continuous real-time continuous glucose monitoring from early pregnancy onwards in highly selected women may reduce the risk of severe hypoglycaemia. Other elements of focused intervention probably also contribute to the risk reduction., (© 2013 The Authors. Diabetic Medicine © 2013 Diabetes UK.)
- Published
- 2014
- Full Text
- View/download PDF
20. Real-time continuous glucose monitoring during labour and delivery in women with Type 1 diabetes - observations from a randomized controlled trial.
- Author
-
Cordua S, Secher AL, Ringholm L, Damm P, and Mathiesen ER
- Subjects
- Adult, Blood Glucose metabolism, Blood Glucose Self-Monitoring methods, Female, Humans, Infant, Newborn, Perinatal Care, Pregnancy, Prenatal Diagnosis methods, Retrospective Studies, Diabetes Mellitus, Type 1 blood, Hyperglycemia diagnosis, Hypoglycemia diagnosis, Obstetric Labor Complications diagnosis, Pregnancy in Diabetics blood
- Abstract
Aims: To explore whether real-time continuous glucose monitoring during labour and delivery supplementary to hourly self-monitored plasma glucose in women with Type 1 diabetes reduces the prevalence of neonatal hypoglycaemia., Methods: Women with Type 1 diabetes participating in a randomized controlled trial on the effect of real-time continuous glucose monitoring in pregnancy were included in this study. Twenty-seven of 60 (45%) women in the intervention arm used real-time continuous glucose monitoring during labour and delivery, supplementary to hourly self-monitored plasma glucose. Real-time continuous glucose monitoring glucose data covering the last 8 h prior to delivery were retrospectively evaluated, and maternal hypo- and hyperglycaemia were defined as glucose values ≤ 3.9 mmol/l and > 7.0 mmol/l, respectively. Women in the control arm (n = 59) solely used self-monitored plasma glucose. Neonatal hypoglycaemia was defined as a 2-h plasma glucose < 2.5 mmol/l., Results: In infants of women using real-time continuous glucose monitoring during labour and delivery, 10 (37%) developed neonatal hypoglycaemia vs. 27 (46%) infants in the control arm (P = 0.45). Among 10 infants with and 17 infants without neonatal hypoglycaemia within the real-time continuous glucose monitoring arm, median maternal self-monitored plasma glucose was 6.2 (range 4.2-7.8) vs. 5.6 (3.3-8.5) mmol/l (P = 0.26) during labour and delivery, with maternal hyperglycaemia present in 17 (0-94) vs. 4 (0-46)% of the time (P = 0.02), and birthweight was 4040 (3102-4322) vs. 3500 (1829-4320) g (P = 0.04). Maternal hypoglycaemia up to delivery was relatively rare., Conclusions: The prevalence of neonatal hypoglycaemia was comparable between infants of women using real-time continuous glucose monitoring supplementary to self-monitored plasma glucose during labour and delivery and infants of women solely using self-monitored plasma glucose., (© 2013 The Authors. Diabetic Medicine © 2013 Diabetes UK.)
- Published
- 2013
- Full Text
- View/download PDF
21. Severe hypoglycemia in pregnant women with type 2 diabetes-A relevant clinical problem.
- Author
-
Secher AL, Mathiesen ER, Andersen HU, Damm P, and Ringholm L
- Subjects
- Blood Glucose metabolism, Diabetes Mellitus, Type 2 drug therapy, Female, Humans, Pregnancy, Pregnancy Trimesters, Pregnancy in Diabetics drug therapy, Risk Factors, Diabetes Mellitus, Type 2 complications, Hypoglycemia prevention & control, Insulin administration & dosage, Pregnancy in Diabetics blood
- Published
- 2013
- Full Text
- View/download PDF
22. The incidence of severe hypoglycaemia in pregnant women with type 1 diabetes mellitus can be reduced with unchanged HbA1c levels and pregnancy outcomes in a routine care setting.
- Author
-
Ringholm L, Secher AL, Pedersen-Bjergaard U, Thorsteinsson B, Andersen HU, Damm P, and Mathiesen ER
- Subjects
- Blood Glucose metabolism, Blood Glucose Self-Monitoring, Cohort Studies, Female, Glucagon therapeutic use, Glucose therapeutic use, Humans, Insulin therapeutic use, Pregnancy, Pregnancy Outcome, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 1 drug therapy, Glycated Hemoglobin metabolism, Hypoglycemia blood, Hypoglycemia drug therapy
- Abstract
Aims: To investigate whether the incidence of severe hypoglycaemia in pregnant women with type 1 diabetes can be reduced without deteriorating HbA1c levels or pregnancy outcomes in a routine care setting., Methods: Two cohorts (2004-2006; n=108 and 2009-2011; n=104) were compared. In between the cohorts a focused intervention including education of caregivers and patients in preventing hypoglycaemia was implemented. Women were included at median 8 (range 5-13) weeks. Severe hypoglycaemia (requiring assistance from others) was prospectively reported in structured interviews., Results: In the first vs. second cohort, severe hypoglycaemia during pregnancy occurred in 45% vs. 23%, p=0.0006, corresponding to incidences of 2.5 vs. 1.6 events/patient-year, p=0.04. Unconsciousness and/or convulsions occurred at 24% vs. 8% of events. Glucagon and/or glucose injections were given at 15% vs. 5% of events. At inclusion HbA1c was comparable between the cohorts while in the second cohort fewer women reported impaired hypoglycaemia awareness (56% vs. 36%, p=0.0006), insulin dose in women on multiple daily injections was lower (0.77 IU/kg (0.4-1.7) vs. 0.65 (0.2-1.4), p=0.0006) and more women were on insulin analogues (rapid-acting 44% vs. 97%, p<0.0001; long-acting 6% vs. 76%, p<0.0001) and insulin pumps (5% vs. 23%, p<0.0001). Pregnancy outcomes were similar in the two cohorts., Conclusions: A 36% reduction in the incidence of severe hypoglycaemia in pregnancy with unchanged HbA1c levels and pregnancy outcomes was observed after implementation of focused intervention against severe hypoglycaemia in a routine care setting. Improved insulin treatment, increased health professional education and fewer women with impaired hypoglycaemia awareness may contribute., (Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
23. The effect of real-time continuous glucose monitoring in pregnant women with diabetes: a randomized controlled trial.
- Author
-
Secher AL, Ringholm L, Andersen HU, Damm P, and Mathiesen ER
- Subjects
- Adult, Blood Glucose metabolism, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Female, Glycated Hemoglobin metabolism, Humans, Hypoglycemic Agents therapeutic use, Pregnancy, Pregnancy Outcome, Treatment Outcome, Young Adult, Blood Glucose Self-Monitoring methods, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 2 blood
- Abstract
Objective: To assess whether intermittent real-time continuous glucose monitoring (CGM) improves glycemic control and pregnancy outcome in unselected women with pregestational diabetes., Research Design and Methods: A total of 123 women with type 1 diabetes and 31 women with type 2 diabetes were randomized to use real-time CGM for 6 days at 8, 12, 21, 27, and 33 weeks in addition to routine care, including self-monitored plasma glucose seven times daily, or routine care only. To optimize glycemic control, real-time CGM readings were evaluated by a diabetes caregiver. HbA1c, self-monitored plasma glucose, severe hypoglycemia, and pregnancy outcomes were recorded, with large-for-gestational-age infants as the primary outcome., Results: Women assigned to real-time CGM (n = 79) had baseline HbA1c similar to that of women in the control arm (n = 75) (median 6.6 [range 5.3-10.0] vs. 6.8% [5.3-10.7]; P = 0.67) (49 [34-86] vs. 51 mmol/mol [34-93]). Forty-nine (64%) women used real-time CGM per protocol. At 33 weeks, HbA1c (6.1 [5.1-7.8] vs. 6.1% [4.8-8.2]; P = 0.39) (43 [32-62] vs. 43 mmol/mol [29-66]) and self-monitored plasma glucose (6.2 [4.7-7.9] vs. 6.2 mmol/L [4.9-7.9]; P = 0.64) were comparable regardless of real-time CGM use, and a similar fraction of women had experienced severe hypoglycemia (16 vs. 16%; P = 0.91). The prevalence of large-for-gestational-age infants (45 vs. 34%; P = 0.19) and other perinatal outcomes were comparable between the arms., Conclusions: In this randomized trial, intermittent use of real-time CGM in pregnancy, in addition to self-monitored plasma glucose seven times daily, did not improve glycemic control or pregnancy outcome in women with pregestational diabetes.
- Published
- 2013
- Full Text
- View/download PDF
24. Patient satisfaction and barriers to initiating real-time continuous glucose monitoring in early pregnancy in women with diabetes.
- Author
-
Secher AL, Madsen AB, Ringholm L, Barfred C, Stage E, Andersen HU, Damm P, and Mathiesen ER
- Subjects
- Adult, Denmark epidemiology, Diabetes Mellitus, Type 1 epidemiology, Diabetes Mellitus, Type 2 epidemiology, Female, Humans, Pregnancy, Pregnancy in Diabetics epidemiology, Prenatal Care, Surveys and Questionnaires, Blood Glucose metabolism, Blood Glucose Self-Monitoring methods, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 2 blood, Patient Satisfaction statistics & numerical data, Pregnancy in Diabetics blood
- Abstract
Aim: To evaluate self-reported satisfaction and barriers to initiating real-time continuous glucose monitoring in early pregnancy among women with pregestational diabetes., Methods: Fifty-four women with Type 1 diabetes and 14 women with Type 2 diabetes were offered continuous glucose monitoring for 6 days at median 9 (range 6-14) gestational weeks and were asked to answer a semi-structured questionnaire on patient satisfaction., Results: Median HbA1c was 49 (range 34-86) mmol/mol) [6.6 (5.3-10.0) %] and duration of diabetes was 12 (0.5-37) years. Continuous glucose monitoring was used for 6 (0.5-7) days, with 43 (65%) women using continuous glucose monitoring for at least 5 days. The women experienced 2.7 (0-12) alarms per 24 h, of which approximately one third was technical alarms and one third disturbed their sleep. Sixteen women (24%) reported discomfort with continuous glucose monitoring during daytime and twelve (18%) during sleep. Many women reported improved diabetes understanding (52%) and would recommend continuous glucose monitoring to others (83%). Twenty-four patients (36%) had continuous glucose monitoring removed earlier than planned ( before the intended 6 days of initial monitoring). Ten women (15%) did not wish to use continuous glucose monitoring again in pregnancy. Main causes behind early removal of continuous glucose monitoring were self-reported skin irritation, technical problems and continuous glucose monitoring inaccuracy. No differences were found in continuous glucose monitoring use, inconvenience or compliance with respect to diabetes type., Conclusions: The majority of pregnant women with diabetes found real-time continuous glucose monitoring useful and the intervention was equally tolerated regardless of diabetes type. Nevertheless, continuous glucose monitoring was frequently removed earlier than planned, primarily because of skin irritation, technical problems and inaccuracy., (© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK.)
- Published
- 2012
- Full Text
- View/download PDF
25. [Continuous glucose monitoring in pregnancies complicated by diabetes].
- Author
-
Madsen AB, Secher AL, Damm P, and Mathiesen ER
- Subjects
- Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 2 complications, Female, Humans, Hypoglycemia prevention & control, Monitoring, Ambulatory, Pregnancy, Pregnancy Complications prevention & control, Pregnancy Outcome, Prenatal Care methods, Risk Factors, Blood Glucose analysis, Blood Glucose Self-Monitoring instrumentation, Blood Glucose Self-Monitoring methods, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 2 blood, Pregnancy in Diabetics blood
- Abstract
In this review the use of continuous glucose monitoring (CGM) in pregnancy complicated by type 1 and type 2 diabetes is examined. Fourteen relevant articles were identified. Observational studies demonstrated that CGM was feasible during pregnancy without severe side effects. One randomised controlled trial resulted in improved metabolic control and reduced risk of macrosomia in women randomised to CGM. Future studies on the use of CGM in pregnancy are awaited with interest.
- Published
- 2011
26. Continuous glucose monitoring-enabled insulin-pump therapy in diabetic pregnancy.
- Author
-
Secher AL, Schmidt S, Nørgaard K, and Mathiesen ER
- Subjects
- Adult, Blood Glucose analysis, Feasibility Studies, Female, Glycated Hemoglobin analysis, Humans, Infant, Newborn, Monitoring, Ambulatory, Pregnancy, Term Birth, Diabetes Mellitus, Type 1 drug therapy, Hypoglycemic Agents therapeutic use, Insulin therapeutic use, Insulin Infusion Systems, Pregnancy in Diabetics drug therapy
- Abstract
We describe the feasibility of continuous glucose monitoring (CGM)-enabled insulin-pump therapy during pregnancy in a woman with type 1 diabetes, who was treated with CGM-enabled insulin-pump therapy in her third pregnancy. During her first pregnancy, the woman was treated with multiple daily injections and baseline HbA1c was 8.9%. Due to pre-eclampsia, the child was born preterm, and had neonatal hypoglycemia. In the planning of the second pregnancy, insulin-pump therapy was initiated, resulting in an HbA1c of 6.8% in early pregnancy. Due to pre-eclampsia, the second child was born preterm, but without neonatal morbidity. Before her third pregnancy, CGM-enabled insulin-pump therapy was introduced, and HbA1c was 6.4% in early pregnancy. The patient was satisfied with this therapy, pre-eclampsia did not occur, and the child was born at term without neonatal morbidity. CGM-enabled insulin-pump therapy appears feasible in diabetic pregnancies.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.